Elizabeth Fabre

7PUBLICATIONS
26CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 11, 2026
End-of-life management and causes of death in ALK-positive non-small cell lung cancer in France: a multicentric analysis.

|Jan 07, 2025
Analysis of the benefit of anti-PD-1 monotherapy according to NGS-diagnosed genetic alterations in patients with non-small cell lung cancer.

Hortense De Saint Basile, Reza Elaidi, Zineb Maaradji

|Oct 21, 2024
Efficacy of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.

Gary Birsen, Valérie Gounant, Nicolas Girard

|Dec 09, 2023
Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond Progression.

Ivan Pourmir, Reza Elaidi, Zineb Maaradji

|Mar 29, 2023
Immunotherapy for Solid Tumors.

Hortense de Saint Basile, Zineb Maaradji, Elizabeth Fabre

|Oct 23, 2021
EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy.

Samy Chelabi, Xavier Mignard, Karen Leroy

Pageof 2

Frequent Collaborators

3 joint publications

Karen Leroy

3 joint publications

Etienne Giroux-Leprieur

2 joint publications

Boris Duchemann

2 joint publications

Gary Birsen